Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.
Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and announces $387 price target.